Skip to main content
MAXCYTE, INC. logo

MAXCYTE, INC. — Investor Relations & Filings

Ticker · MXCT ISIN · US57777K1060 LEI · 54930053YHXULRFCU991 US Professional, scientific and technical activities
Open in API
Filings indexed 767 across all filing types
Latest filing 2019-11-07 Regulatory Filings
Country US United States of America
Listing US MXCT

About MAXCYTE, INC.

https://www.maxcyte.com/

MaxCyte, Inc. is a cell-engineering company that provides enabling platform technologies to advance the discovery, development, and commercialization of cell-based therapeutics. Its core offering is the ExPERT™ platform, which utilizes proprietary Flow Electroporation® technology for efficient, scalable, and non-viral transfection of complex cells. This technology supports a wide range of applications, including cell therapy, gene editing, antibody and protein production, and vaccine development. Additionally, MaxCyte offers SeQure™ genotoxicity assessment services to evaluate the safety of gene-edited products by detecting on- and off-target effects. The company employs a partnership-driven licensing model to support clients from early-stage research through to clinical and commercial manufacturing.

Recent filings

Filing Released Lang Actions
MaxCyte to Present at BIO-Europe 2019
Regulatory Filings Classification · 98% confidence The document is a short announcement (under 5,000 characters) issued via the Regulatory News Service (RNS) regarding a company executive's upcoming presentation at a conference. It does not contain the presentation materials themselves, nor does it fit into specific categories like financial reports or shareholder voting results. As it is a general regulatory announcement that does not fall into a more specific category, it is classified as a Regulatory Filing (RNS).
2019-11-07 English
Result of AGM
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a short announcement from MaxCyte, Inc. regarding the 'Result of AGM' (Annual General Meeting). It explicitly states that all resolutions were duly passed at the meeting held the previous day. This falls under the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2019-11-01 English
MaxCyte Advances Phase I Clinical Trial
Regulatory Filings Classification · 100% confidence The document is a press release issued via the London Stock Exchange's Regulatory News Service (RNS). It provides a corporate update regarding the progress of a Phase I clinical trial for the company's CARMA platform. Since it is a general regulatory announcement regarding company operations and clinical trial milestones that does not fit into specific categories like financial reports, dividends, or board changes, it is classified as a Regulatory Filing (RNS).
2019-10-24 English
Presentations at Cell & Gene Therapy Congress
Regulatory Filings Classification · 98% confidence The document is an RNS (Regulatory News Service) announcement from MaxCyte, Inc. regarding their participation and upcoming presentations at the 5th Annual Cell & Gene Therapy Congress. It does not contain financial results, board changes, or specific regulatory filings, but rather serves as a general corporate update/announcement distributed via the London Stock Exchange's regulatory news service. As it does not fit into more specific categories like 'Investor Presentation' (which would be the slides themselves) or 'Earnings Release', it is classified as a general Regulatory Filing.
2019-10-23 English
Notification of AGM and Audit Declaration
AGM Information Classification · 98% confidence The document is a short announcement (under 5,000 characters) issued via RNS (Regulatory News Service) regarding the upcoming Annual General Meeting (AGM) and the disclosure of auditor remuneration. It explicitly states that formal notice and resolutions have been circulated to shareholders and are available on the company website. Per the 'Menu vs Meal' rule, this is an announcement of materials rather than the materials themselves, and it serves as a notification of an upcoming meeting and related governance disclosures.
2019-10-08 English
Editas Clinical and Commercial License Agreement
Regulatory Filings Classification · 98% confidence The document is a press release issued via the Regulatory News Service (RNS) of the London Stock Exchange. It announces a clinical and commercial license agreement between MaxCyte, Inc. and Editas Medicine. Since this is a corporate announcement regarding a business partnership/licensing deal and does not fit into specific categories like M&A (which usually implies a takeover or merger) or other specialized financial reports, it falls under the 'Regulatory Filings' (RNS) category as a general corporate announcement.
2019-10-07 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.